Search Results for: 19

— First-in-Class Drug Candidate to Prevent C. difficile Ahead of Schedule for Phase 2 Testing to Begin in 1st Quarter 2015 — ROCKVILLE, Md., Dec. 22, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline […]

— First-in-Class Clinical Program Targets Protection of Microbiome to Prevent Overgrowth of Deadly C. difficile Infection Linked with Use of IV Antibiotics — ROCKVILLE, Md., Dec. 2, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that

— Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria — ROCKVILLE, Md., Nov. 24, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that

— Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS — — Conference Call Today, November 14, 2014, at 8:30 a.m. (EST); U.S. Participants Call (888) 347-5280 or Join Webcast at http://www.videonewswire.com/event.asp?id=100975 — ROCKVILLE, Md., Nov. 14, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT:

— First Allowed Patent Application Directly Related to SYN-004 in the U.S. — ROCKVILLE, Md., Oct. 22, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel pathogen-specific therapies for serious infections and diseases, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a composition

— Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman — ROCKVILLE, Md., Oct. 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, announced today the expansion of its Clinical Advisory Board (CAB) created to support

ROCKVILLE, Md., Oct. 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel biologics and drugs targeting specific pathogens that cause serious infections and diseases, announced today that it has executed definitive purchase agreements with select institutional investors for gross proceeds of approximately $20.7 million in a registered direct offering of

— Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action — ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company’s Investor Day in New

— Company Expects to File IND to Support Clinical Trials in Mid-2015 — ROCKVILLE, Md., Sept. 12, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration (FDA) has

— Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT — ROCKVILLE, Md., Sept. 11, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference